Barbara Ryan

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.

While Q3 numbers look bleak, is improvement on the horizon?

When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.

But could there be a shift in momentum?

A remarkable run indeed, but cost questions can’t be ignored.

What are the reasons behind the slump and what does the future hold?

Adding context to Pfizer’s orbit-busting, first-quarter earnings.

More capital gains and the potential strains for rest of 2021.

Amid vaccine heroics, its complex story may finally be resonating.

Dueling paths leave market fortunes uncertain.

Tone still set on the market catalysts to look for in 2021.

Vaccine strides, likely pricing impasse point to optimism for 2021.

Biopharma raises an unprecedented $100 billion.

When the people are the sole assets.

The key factors behind the sector’s strong surge in new equity fundraisings.

Latest reform brouhaha requires a united response focused on real solutions.

Embracing expanded digital models key to future ROI.

Now is the time, the world is listening.

Rocked by pandemic, can companies protect their bottom line?

In the next three months it is likely that three healthcare companies will face crucial activist votes. At Alere Inc., Coppersmith Capital Management, LLC wants the company to sell/divest assets which it believes could allow them to pay down over $3B in debt. In response, Alere is mounting a Hess style defense, nominating four new directors.